MedPath

Elanco's Credelio Quattro Breaks New Ground in Multi-Parasite Protection for Dogs

• Elanco Animal Health's Credelio Quattro, a novel oral therapy combining four active ingredients, has received FDA approval for protecting dogs against six types of parasites.

• The groundbreaking therapy is the first isoxaline insecticide to include tapeworm coverage, demonstrating 100% efficacy in heartworm and tapeworm prevention in laboratory studies.

• The meat-flavored, chewable tablet is approved for dogs and puppies 8 weeks and older weighing at least 3.3 pounds, offering comprehensive parasite protection in a single dose.

Elanco Animal Health has launched a groundbreaking parasite protection therapy that marks a significant advancement in veterinary medicine. The FDA-approved Credelio Quattro, unveiled at the 2025 Veterinary Meeting & Expo in Orlando, Florida, offers comprehensive protection against six parasites, including three intestinal worms with zoonotic potential.
The innovative therapy combines four active ingredients - lotilaner, moxidectin, praziquantel, and pyrantel - in a palatable, meat-flavored chewable tablet. What sets Credelio Quattro apart is its distinction as the first and only isoxaline insecticide to incorporate tapeworm coverage, representing a significant leap forward in parasite control.

Clinical Efficacy and Safety Profile

Laboratory studies have demonstrated impressive efficacy rates, with Credelio Quattro achieving 100% prevention against both heartworm disease and tapeworms. The treatment maintains consistent effectiveness throughout the monthly dosing period, particularly in its action against fleas and ticks.
Dr. Casey Locklear, US medical strategic lead for Elanco Animal Health and practicing veterinarian in Texas, emphasized the product's broad spectrum of protection: "Credelio Quattro is the broadest isoxaline insecticide, offering coverage against six types of parasites, including tapeworms."

Treatment Specifications and Accessibility

The medication is approved for use in dogs and puppies aged 8 weeks and older, with a minimum weight requirement of 3.3 pounds. The formulation is specifically designed to be meat allergen-free while maintaining palatability.
Healthcare providers and veterinarians can access detailed product information through credelioquattrovet.com. Elanco is featuring the product at the WVC veterinary conference in Las Vegas, where renowned experts Dr. Susan Little and Dr. Brian Herrin will lead educational sessions on the therapy's applications and benefits.

Market Impact and Educational Initiatives

The launch of Credelio Quattro represents a significant milestone in veterinary parasitology, offering veterinarians a comprehensive solution for parasite control in a single, convenient formulation. Elanco's commitment to education is evident through their planned conference presentations and daily "quattro hour" information sessions at their booth during the WVC conference.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Albendazole-Ivermectin Combination Shows Promise Against Intestinal Worms in Phase II/III Trial

A fixed-dose combination of albendazole and ivermectin demonstrates superior efficacy against soil-transmitted helminths compared to albendazole alone.
The ALIVE clinical trial, conducted across three African countries, showed high cure rates for Trichuris trichiura and hookworm infections with the combination therapy.

Corcept Therapeutics Submits New Drug Application for Relacorilant to Treat Cushing's Syndrome

Corcept Therapeutics has submitted a New Drug Application to the FDA for relacorilant, a selective cortisol modulator designed to treat patients with endogenous hypercortisolism (Cushing's syndrome).
The application is supported by positive results from multiple clinical trials, including the pivotal GRACE trial, Phase 3 GRADIENT study, and long-term extension studies, demonstrating improvements in various symptoms with an acceptable safety profile.

Loyal's LOY-002 Receives FDA's RXE Acceptance for Canine Lifespan Extension

Loyal's LOY-002, a drug aimed at extending the healthy lifespan of senior dogs, has received acceptance from the FDA for its Reasonable Expectation of Effectiveness (RXE).
The drug targets age-related metabolic dysfunction in dogs aged 10 years and older, weighing at least 14 lbs, with the goal of improving their quality of life.

Crofelemer Receives FDA Orphan Drug Designation for Cholera-Related Diarrhea

The FDA has granted orphan-drug designation to crofelemer for treating diarrhea in cholera, a rare condition in the U.S.
This designation provides Jaguar Health with development incentives, including tax credits and marketing exclusivity.

Cumberland Pharma Reports Key Clinical and Business Developments in November 2024

Cumberland Pharma has announced significant milestones in November 2024, including new research findings, expanded Medicaid coverage, and product access improvements. Highlights include favorable outcomes for Caldolor® compared to ketorolac, FDA designations for Ifetroban targeting Duchenne Muscular Dystrophy, advancements in delirium treatment, and efforts to combat antimicrobial resistance with Vibativ®.

Fortress Biotech's Emrosi Receives FDA Approval for Rosacea Treatment

The FDA approved Emrosi (minocycline hydrochloride extended-release capsules, 40mg) for treating inflammatory lesions of rosacea in adults, marking Fortress Biotech's first FDA approval.
Clinical data presented at the Fall Clinical Dermatology Conference showed Emrosi provides higher dermal concentration than doxycycline, potentially leading to clinically meaningful impact.

FDA Grants Renewal for Canalevia-CA1 for Canine Chemotherapy-Induced Diarrhea

The FDA has approved the renewal of Canalevia-CA1 (cofelemer delayed-release tablets) for treating chemotherapy-induced diarrhea (CID) in dogs.
Canalevia-CA1, developed by Jaguar Health, is administered orally twice daily for at-home treatment of CID in canine patients.

FDA Renews Conditional Approval for Jaguar Health's Canalevia-CA1 to Treat CID in Dogs

The FDA has renewed the conditional approval for Jaguar Health's Canalevia-CA1, extending its market availability for treating chemotherapy-induced diarrhea (CID) in dogs until December 2025.
Canalevia-CA1, a plant-based oral treatment derived from the Croton lechleri tree, is the only FDA conditionally approved drug for CID in canines, offering a crucial option for veterinary care.

Elanco's Credelio Quattro Receives FDA Approval for Broad-Spectrum Parasite Protection in Dogs

Elanco's Credelio Quattro gains FDA approval as the broadest canine oral parasiticide, targeting six parasite types in a single monthly dose.
The chewable tablet protects against fleas, ticks, heartworms, roundworms, hookworms, and multiple tapeworm species, addressing a gap in existing treatments.

Elanco's Zenrelia (Ilunocitinib) Receives FDA Approval for Canine Dermatitis

Elanco's Zenrelia (ilunocitinib) has gained FDA approval as a once-daily oral treatment for pruritus associated with allergic dermatitis and atopic dermatitis in dogs.
A randomized, double-blind study demonstrated Zenrelia's noninferiority to a market-leading JAK inhibitor in relieving itch and skin lesions in dogs with atopic dermatitis.

Reference News

[1]
Novel therapy protects against 6 parasites
dvm360.com · Feb 25, 2025
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy